MRK Stock Recent News
MRK LATEST HEADLINES
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=143030&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK , April 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=142992&wire=1 or contact Joseph E. Levi, Esq.
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
LOS ANGELES--(BUSINESS WIRE)--MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=142959&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=142847&wire=1 or contact Joseph E. Levi, Esq.